CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TrickE3 focuses on developing innovative methods for creating monovalent degraders that can induce the degradation of hard-to-target proteins, particularly in pancreatic ductal adenocarcinoma. By enhancing our understanding of E3 ubiquitin ligases, the project aims to expand drug discovery and address unmet clinical ne…
Classical drug design relies mostly on the availability of accessible pockets to block specific protein activities.
Despite tremendous progress, more than 80% of all human proteins remain beyond the reach of traditional inhibitor-centric approaches.
Chemical ablation of protein abundance using bivalent degraders (PROTACs) moves away from an occupancy-driven (inhibition) to an event-driven (binding) pharmacology.
However, their design is intrinsically limited to targets that are ligandable via ch…
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
